Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reissue Patent
2001-03-19
2003-11-25
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
Reissue Patent
active
RE038332
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to novel esters of hydroxyl-containing indolocarbazoles and acids containing selected solubilizing groups, to compositions including the indolocarbazole esters and to methods for the use of the indolocarbazole esters in the elucidation and understanding of certain diseases, including diseases of the prostate.
BACKGROUND OF THE INVENTION
Indolocarbazoles are a well-known class of small molecules. In animal studies, activity of indolocarbazoles as therapeutic agents in the treatment of pathological disorders of the prostate have been demonstrated. Additionally, indolocarbazoles are useful as inhibitors of protein kinases C, A and G, myosin light chain kinase, and trk, a tyrosine kinase activated by neurotrophins. Indolocarbazoles have been also shown to be active neurologic agents.
U.S. Pat. No. 4,877,776 describes indolocarbazole derivatives which exhibit protein kinase C-inhibiting activity. U.S. Pat. No. 4,923,986 and PCT patent specification WO94/02488 describe physiologically-active indolocarbazole derivatives having anti-tumor activities. PCT patent specification WO94/27982 describes the use of indolocarbazole derivatives to treat a pathological condition of the prostate gland in a mammal. Japanese Patent Specification JP63-295588 describes indolocarbazole derivatives which are inhibitors of protein kinase C. PCT patent specification WO93/08809 describes indolocarbazole derivatives which potentiate neurotrophic activity. PCT patent specification WO94/06799 describes indolocarbazole derivatives as therapeutic agents for thrombocytopenia.
A significant problem which has limited the usefulness of indolocarbazoles as therapeutic and research reagents is their poor solubility in aqueous solutions. In light of the significant useful activities of indolocarbazoles, there is a need for novel indolocarbazole derivatives which achieve the beneficial effects of indolocarbazoles and which have increased aqueous solubility. Such compounds would allow for in vivo delivery of indolocarbazole-containing solutions without creating additional problems for the recipient. This invention is directed to this important end.
SUMMARY OF THE INVENTION
The present invention provides novel soluble esters of hydroxyl-containing indolocarbazoles. The subject invention also includes compositions including the indolocarbazole esters, and methods for the use of the indolocarbazole esters in the treatment of diseases, including pathological conditions of the prostate gland.
In one aspect, compounds are provided having the formula Q—L—C(═O)—A wherein A is a solubilizing group, L is oxygen and Q is an indolocarbazole residue of Formula I:
Constituent members are defined infra, as well as preferred constituent members.
The compounds of the invention are useful in a variety of applications. For example, the compounds may be employed in research applications to understand, for example, the mechanistic aspect of the therapeutic benefits derived therefrom, i.e., in the exploitation of scientific understanding of how these small molecules effectuate a positive result on certain cancerous tumors. Additionally, particularly preferred compounds of the invention can be utilized as a screening tool to discover other small molecules which offer equivalent efficacious results in in vitro and in vivo models of disease states of interest.
In a clinical setting, compositions comprising the claimed compounds are preferably used as therapeutics for treating a pathological condition of the prostate gland, e.g., benign prostatic hypertrophy or prostate cancer; compositions comprising the claimed invention are also useful as therapeutics for the treatment of neurological diseases.
These and other features of the compounds will be set forth in expanded form as the disclosure continues.
REFERENCES:
patent: 4877776 (1989-10-01), Murakata et al.
patent: 4923986 (1990-05-01), Murakata et al.
patent: 5461146 (1995-10-01), Lewis et al.
patent: 5650407 (1997-07-01), Mallamo et al.
patent: 5686444 (1997-11-01), Mallamo et al.
patent: 63-295588 (1988-01-01), None
patent: WO 93/08809 (1993-05-01), None
patent: WO 94/02488 (1994-03-01), None
patent: WO 94/06799 (1994-03-01), None
patent: WO 94/20106 (1994-09-01), None
patent: WO 94/27982 (1994-12-01), None
Akinaga, S., et al., “Antitumor effect of KT6124, a novel derivative of protein kinase inhibitor K-252a, and its mechanism of action,”Cancer Chemother Pharm., 1992, 266-272.
Isaacs, J. et al., “Establishment and Characterization of Seven Dunning Rat Prostatic Cancer Cell Lines and Their Use in Developing Methods for Predicting Metastatic Abilities of Prostatic Cancers”,The Prostate1986, 9, 261-281.
Greene and Wuts, “Protective Groups in Organic Synthesis”, 2nd ed., Wiley & Sons, New York, 1991.
Joyce, et al., “Synthesis of the aromatic and monosaccaride moieties of staurosporin,”J. Org. Chem., 1987, 52(7), 1177-1183.
March, J., “Advanced Organic Chemistry”, 3rd Edition, Wiley & Sons, New York, 1985.
“Remington's Pharmaceutical Sciences”, Mack Publishing Co., Easton, PA, 1980.
Hudkins Robert L.
Mallamo John P.
Cephalon Inc.
Woodcock & Washburn LLP
LandOfFree
Selected soluble esters of hydroxyl-containing indolocarbazoles does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Selected soluble esters of hydroxyl-containing indolocarbazoles, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selected soluble esters of hydroxyl-containing indolocarbazoles will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3182954